Almost All Hopes Dashed For Pfizer/Medivation's Dimebon
This article was originally published in The Pink Sheet Daily
Executive Summary
After a disastrous failure in Alzheimer's disease last year, Dimebon once again disappoints in a Phase III trial - this time in Huntington disease.
You may also be interested in...
Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble
Since Gilead’s $11 billion buyout of Pharmasset in late 2011, large- and mid-cap biotech share prices have been on the rise. Plus news on recent financing activity by Ophthotech, Effector Therapeutics, Karyopharm Therapeutics and Ironwood Pharmaceuticals.
Hopes For Disease Modification In Huntington’s Disease
A group at the Lawrence Berkeley National Laboratory believes that a synthetic antioxidant previously shown to reduce apoptosis and enhance cell survival in vitro can ameliorate the symptoms of Huntington’s Disease – and beyond its neuroprotective effects, may even have disease modifying properties. They’ve published the first proof of concept in animals, aiming to bring the compound into human studies.
Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.